Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering and a concurrent private placement, aiming to raise approximately $2.9 million in gross proceeds. The offerings include 3,625,000 common shares priced at $0.795 each and warrants to purchase an equal number of shares at an exercise price of $0.84 per share, with the warrants priced at $0.005 each. The transactions are expected to close on or about Aug. 14, 2026, subject to customary closing conditions.
The net proceeds from these offerings, combined with existing cash, cash equivalents, restricted cash, and investment-grade securities, will be used for working capital and general corporate purposes. This capital infusion is a strategic move for Dyadic as it continues to advance its proprietary Dapibus and C1 expression systems, which are designed to enable rapid, cost-effective, and flexible manufacturing of high-value proteins. These platforms are intended to address the growing global demand for non-animal proteins across the life sciences, food and nutrition, and bio-industrial markets.
The significance of this funding lies in its potential to accelerate Dyadic's research and development efforts and commercial expansion. By securing additional capital, the company can invest in scaling its technologies, which could position it to capitalize on the increasing shift toward sustainable and animal-free protein production. This is particularly relevant as industries face pressures to adopt more environmentally friendly and ethically sound manufacturing processes.
Dyadic's C1 expression system, derived from a fungus, offers a robust alternative to traditional mammalian cell-based production, potentially reducing costs and improving yields for biologics and other proteins. The Dapibus platform is tailored for the production of enzymes and other industrial proteins, broadening the company's market reach. The successful execution of this capital raise could enable Dyadic to bring these technologies closer to commercial viability, offering customers more efficient and scalable solutions.
Investors and industry observers will be watching how Dyadic utilizes these funds to advance its pipeline and partnerships. The company's focus on non-animal protein production aligns with broader trends toward sustainability and biomanufacturing innovation, making this development noteworthy for those tracking the biotech and food technology sectors. Aegis Capital Corp. served as the exclusive placement agent for the offerings, underscoring the institutional interest in Dyadic's growth prospects.
For more details on the offering, interested parties can view the full press release at https://ibn.fm/od7FJ. Additional information about Dyadic International is available on its website at https://dyadic.com/.
